Liperial

Fenofibrate, the active ingredient in Liperial, is a fibric acid derivative presented as an oral tablet for oral use. It belongs to the lipid‑lowering therapeutic class and is marketed in the European Union for the treatment of hypertriglyceridemia, mixed dyslipidemia and hypercholesterolemia in adult patients, aiming to improve lipid profiles and reduce cardiovascular risk.

GNH USA supplies Liperial as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution and ensuring consistent quality across global markets.

Fenofibrate is used to manage disorders of lipid metabolism, particularly elevated triglyceride and cholesterol levels.

- Hypertriglyceridemia: lowers high triglyceride concentrations in the blood. - Mixed dyslipidemia: improves both triglyceride and LDL/HDL cholesterol profiles. - Hypercholesterolemia: reduces total and LDL cholesterol levels, supporting overall lipid control.

Fenofibrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain, dyspepsia. - Headache: mild to moderate intensity. - Muscle pain (myalgia): aching or soreness of muscles. - Elevated liver enzymes: increased ALT or AST levels. - Elevated serum creatinine: mild rise in kidney function markers. - Skin rash: mild dermatologic irritation.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with potential kidney injury. - Hepatotoxicity: significant liver injury indicated by marked enzyme elevations. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Gallstones: formation of biliary sludge or stones.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor relevant parameters. - Renal impairment: assess kidney function and adjust therapy as needed. - Hepatic disease: monitor liver enzymes regularly. - Pregnancy and lactation: use only if potential benefits outweigh risks. - Drug interactions: review concomitant medications for possible interactions. - Cardiovascular disease: exercise caution in patients with coronary artery disease. - Store at ambient temperature: keep in original container, protect from moisture.

Fenofibrate can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Gemfibrozil: markedly increases risk of myopathy. - Cyclosporine: may raise fenofibrate plasma concentrations. - Anticoagulants (e.g., warfarin): can enhance anticoagulant effect.

Moderate Interactions (Monitor Closely): - Statins: potential for myopathy; monitor creatine kinase. - Oral contraceptives: may elevate triglyceride levels. - Thiazide diuretics: can affect lipid parameters and renal handling.